Equity Profile

BSX

Boston Scientific Corporation

Health CareHealth Care Equipment$76.9B

Apr22Wed

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:30 AM EDT

Boston Scientific Beats on EPS, Stock Up 8.99%

Metric	Actual	Expected	Surprise
EPS	$0.80	N/A	+0.63%

management commentary, guidance changes, and full analysis available with Pro.

Boston Scientific Beats on EPS, Stock Up 8.99%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.80	N/A	+0.63%

Management Commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook on operational performance. They emphasized the importance of innovation and customer engagement.

Management highlighted strong demand in key product areas.

They expressed confidence in maintaining market share despite challenges.

What It Means

Boston Scientific's strong EPS performance suggests effective cost management and possibly robust sales in certain segments, leading to an 8.99% increase in stock price. The market reacted positively, reflecting investor confidence in the company's ability to navigate challenges. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

Company Snapshot

Boston Scientific Co (BSX) is a leading medical device company that develops and manufactures a wide range of products for various medical fields, including cardiology, urology, and endoscopy. As a key player in the health care sector, the company's innovations help improve patient outcomes and drive advancements in medical technology.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of the company's profitability and will indicate how well Boston Scientific is managing costs and generating income.

N/A

Revenue Growth

Revenue growth is essential to understand the demand for Boston Scientific's products and overall market performance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+5.92%

Avg Stock Reaction

+0.45%

Last Quarter Recap

In the last quarter, Boston Scientific reported an EPS of $0.80, exceeding expectations by nearly 3%. However, the stock experienced a significant drop of 17.59% the following day, indicating market concerns despite the positive earnings surprise.

Management Promises & Guidance

Continue to innovate and expand product offerings in key therapeutic areas.
Focus on improving operational efficiencies to enhance profitability.
Commit to maintaining strong relationships with healthcare providers and stakeholders.

Expectations

Wall Street Expectations

Overall, Wall Street seems cautiously optimistic about Boston Scientific's upcoming earnings, given its history of beating EPS estimates. However, there are concerns about potential revenue growth and market dynamics.

Bull Case

The optimistic view hinges on strong demand for new products and continued market share gains, which could lead to better-than-expected revenue and EPS growth.

Bear Case

Conversely, if revenue growth falls short or if there are signs of increased competition, the stock could face downward pressure, especially given the recent volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate for new product lines?

This will indicate how well Boston Scientific is capturing market demand and expanding its footprint in key therapeutic areas.

How is the company addressing competitive pressures in its core markets?

Understanding the company's strategy to maintain or grow market share will be crucial for assessing future performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of Boston Scientific's recent product launches, which could drive higher-than-expected revenue growth despite competitive pressures.

Supporting Evidence

The company's historical EPS beat rate of 88% suggests a strong track record of exceeding expectations.

Options pricing indicates a significant expected move, which may reflect heightened uncertainty rather than a negative outlook.

Recent product innovations have received positive feedback from healthcare providers, indicating strong market demand.

Key Risk

If revenue growth exceeds 10%, it could challenge the current bearish sentiment and shift market expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to sustain growth amid competitive pressures and market dynamics.

Bull Confirmed If

Revenue growth of 10% or more, indicating strong demand for new products and successful market penetration.

Bear Confirmed If

Revenue growth below 5%, suggesting potential challenges in maintaining market share or demand.

Pre-Earnings Positioning

Options Market

Implied Move

±8.34%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move of over 8% in either direction, reflecting uncertainty about the upcoming earnings report.

Options are pricing ±8.3% while BSX has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

30d HV

36.7%

Calls (1.1M)P/C Ratio: 0.17Puts (190K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Boston Scientific beats expectations and raises guidance, history suggests the stock could see a positive reaction, averaging a 4.85% increase on such outcomes.

In-Line / Cautious

An in-line report with cautious commentary may lead to muted market reactions, as investors assess the implications for future growth.

Miss

If the company misses expectations, history suggests a potential decline of around 5.68%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of new product lines and their contribution to overall revenue.
2Any commentary on competitive dynamics and how the company plans to address them.
3Insights into operational efficiencies and cost management strategies.
4Feedback from healthcare providers regarding product effectiveness and demand.
5Future guidance on revenue and EPS expectations for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr20

CLFReported

Cleveland-Cliffs Inc.

RecapView

Apr20

BOHReported

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of the company's profitability and will indicate how well Boston Scientific is managing costs and generating income.

N/A

Revenue Growth

Revenue growth is essential to understand the demand for Boston Scientific's products and overall market performance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+5.92%

Avg Stock Reaction

+0.45%

Last Quarter Recap

Management Promises & Guidance

Continue to innovate and expand product offerings in key therapeutic areas.
Focus on improving operational efficiencies to enhance profitability.
Commit to maintaining strong relationships with healthcare providers and stakeholders.

Expectations

Wall Street Expectations

Bull Case

The optimistic view hinges on strong demand for new products and continued market share gains, which could lead to better-than-expected revenue and EPS growth.

Bear Case

Conversely, if revenue growth falls short or if there are signs of increased competition, the stock could face downward pressure, especially given the recent volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate for new product lines?

This will indicate how well Boston Scientific is capturing market demand and expanding its footprint in key therapeutic areas.

How is the company addressing competitive pressures in its core markets?

Understanding the company's strategy to maintain or grow market share will be crucial for assessing future performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of Boston Scientific's recent product launches, which could drive higher-than-expected revenue growth despite competitive pressures.

Supporting Evidence

The company's historical EPS beat rate of 88% suggests a strong track record of exceeding expectations.

Options pricing indicates a significant expected move, which may reflect heightened uncertainty rather than a negative outlook.

Recent product innovations have received positive feedback from healthcare providers, indicating strong market demand.

Key Risk

If revenue growth exceeds 10%, it could challenge the current bearish sentiment and shift market expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to sustain growth amid competitive pressures and market dynamics.

Bull Confirmed If

Revenue growth of 10% or more, indicating strong demand for new products and successful market penetration.

Bear Confirmed If

Revenue growth below 5%, suggesting potential challenges in maintaining market share or demand.

Pre-Earnings Positioning

Options Market

Implied Move

±8.34%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move of over 8% in either direction, reflecting uncertainty about the upcoming earnings report.

Options are pricing ±8.3% while BSX has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

30d HV

36.7%

Calls (1.1M)P/C Ratio: 0.17Puts (190K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Boston Scientific beats expectations and raises guidance, history suggests the stock could see a positive reaction, averaging a 4.85% increase on such outcomes.

In-Line / Cautious

An in-line report with cautious commentary may lead to muted market reactions, as investors assess the implications for future growth.

Miss

If the company misses expectations, history suggests a potential decline of around 5.68%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of new product lines and their contribution to overall revenue.
2Any commentary on competitive dynamics and how the company plans to address them.
3Insights into operational efficiencies and cost management strategies.
4Feedback from healthcare providers regarding product effectiveness and demand.
5Future guidance on revenue and EPS expectations for the upcoming quarters.